Kyverna Therapeutics

Today, we shared our Q4 and Full Year 2025 financial results, highlighting our continued leadership in building a first-in-class neuroimmunology CAR T franchise.     Last quarter, we reported landmark topline data of our investigational therapy, miv-cel, in stiff person syndrome (SPS), a serious and debilitating disease with no FDA approved treatments. In addition, we shared positive interim data from the Phase 2 portion of the KYSA-6 clinical trial in generalized myasthenia gravis (gMG) as well as promising data in progressive multiple sclerosis, underscoring the valuable pipeline-in-a-product opportunity we have with miv-cel.    We will present additional data in gMG and SPS at the 2026 American Academy of Neurology (AAN) meeting in April, as we actively prepare for our SPS BLA filing and potential commercial launch.    For more details, read the full release: https://bit.ly/4uVoa1d

We were pleased to recently participate in the San Francisco Myasthenia Gravis Foundation of America, Inc. Community Health Fair and share information about our Phase 3 CAR T-cell therapy clinical trial in generalized myasthenia gravis (gMG), called KYSA-6. Thank you, MGFA, for hosting these events that facilitate community-level education and empower patients living with #myastheniagravis. You can learn more about our KYSA-6 trial by visiting myastheniagravistrials.com. #MG #CARTcelltherapy #autoimmune #neuroimmunology

This Sunday, on #InternationalSPSAwarenessDay, it’s important we come together and shine a light on this rare and progressive autoimmune disease.     At Kyverna, our goal is to provide meaningful clinical outcomes in SPS and other neurological diseases. Together, we can raise awareness, drive innovation forward, and bring hope to those in need.    #neuroimmunology #autoimmunediseases #stiffpersonsyndrome #CARTcelltherapy #raredisease

We look forward to sharing important new data from our neuroimmunology franchise at the American Academy of Neurology (AAN) 2026 Annual Meeting, which will take place from April 18-22, 2026, in Chicago.     This includes two oral presentations from our late-stage clinical programs–the primary analysis from our KYSA-8 registrational trial in stiff person syndrome and updated KYSA-6 Phase 2 data in generalized myasthenia gravis. We hope to see you there!       Read more: https://bit.ly/4lfjKxU   #AAN2026 #AANAM #Neuroimmunology #SPS #MG 

Join our team at upcoming investor conferences in Miami, where we will share our latest company highlights and near-term catalysts. Learn more here: https://bit.ly/4u1hqyB  A live webcast of our fireside chat at Leerink will be made available at ir.kyvernatx.com following the conference.      #Leerink #Jefferies #Biotech

Our Kyverna team wore rare disease colors this week in support of Rare Disease Day. In wearing these colors, we honor the strength of patients, families, caregivers, and advocates who navigate daily life with rare autoimmune and neurological diseases. At Kyverna, our mission is driven by the significant unmet need facing these communities. We’re committed to advancing meaningful innovation with CAR T-cell therapies for patients with rare autoimmune diseases. #RareDiseaseDay #ShareYourColors #AutoimmuneDisease #RareDiseaseCommunity #MoreThanYouCanImagine 

Ahead of Rare Disease Day, we’re shining a spotlight on stiff person syndrome (SPS), a rare and progressive autoimmune disease with life‑altering impact. SPS causes persistent muscle rigidity and painful muscle spasms and can lead to permanent disability and increased risk of mortality. Approximately 80% of patients lose mobility, requiring a wheelchair or walking aid. Many also experience what’s known as a “freezing attack”, and can suddenly fall, leading to hospitalization due to injuries.  In this video excerpt from The Stiff Person Syndrome Research Foundation podcast, Tara Zier, founder of the SPSRF and Amanda Piquet, MD, FAAN, discuss the realities of living with SPS, types of symptoms, and the urgent need for FDA-approved treatment options. At Kyverna, we are committed to supporting the SPS community and potentially bringing a novel therapy to patients and physicians who need an effective treatment for this devastating and progressive disease. Listen to the full interview here: https://bit.ly/4u55Fau  #RareDiseaseDay #RareDiseaseCommunity #SPS #AutoimmuneDisease #MoreThanYouCanImagine

Today, we welcome biotech leaders, Sravan K. Emany and Andrew Miller, PhD, to our Board of Directors. Their expertise in capital strategy, clinical development, and operations will be critical as we advance towards commercialization and prepare for Kyverna’s next phase of growth.  Read more here: https://bit.ly/4kPScPm

We are pleased to see updated data from the Phase 1 investigator-initiated trials (IITs) in patients with progressive multiple sclerosis at #ACTRIMS2026. This promising data with our investigational CAR T-cell therapy, miv-cel, continues to demonstrate the potential of our therapy across multiple autoimmune diseases. View the ACTRIMS abstracts here: https://lnkd.in/gnrBDmdC #Biotech #CARTcelltherapy #MultipleSclerosis

We are pleased to welcome Mayo Pujols as our new Chief Technology Officer. Mr. Pujols brings more than 30 years of technical operations experience to the role, as well as a deep background in leading late-stage and commercial manufacturing for cell and gene therapies. His proven track record of disciplined execution and operational delivery will be instrumental as our team advances towards the potential launch of our investigational therapy, miv-cel, in stiff person syndrome. Read more here: https://bit.ly/4qTTpY2